Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT05119179

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05119179
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05119179. Allocation not applicable; no masking; primary purpose treatment. Start 2021-11-22 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Condition
PreDiabetes
Intervention (Drug)
Semaglutide
Lead sponsor
The University of Texas Health Science Center, Houston (class: other)
Collaborator
Vanderbilt University Medical Center (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05119179
Content hash
440dd68db77d9e4a77b674f31a75c52731e95ecc56244e50414685c7ec85d1ea